Evolent Health, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Evolent Health reported a substantial net loss of $579.4 million and a 26.6% revenue decrease in 2025, driven by contractual changes and a $398.0 million goodwill impairment.
NYSE
10-K: Evolent Health's 10-K Filing Reveals Strategic Shifts and Financial Challenges in Value-Based Care
Evolent Health's 2024 10-K filing highlights strategic shifts towards value-based specialty care, acquisitions, and financial challenges due to rising medical costs.
NYSE
Evolent Health's 2023 annual report details its financial performance, strategic acquisitions, and focus on value-based specialty care.